Frontlight ResearchEarly access
CompletedPhase 1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011
Key facts
- Who runs it
- Innovent Biologics (Suzhou) Co. Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 64 people enrolled
- Started
- 8 Dec 2025
- Ended
- 28 Sept 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- IBI3011
- IBI3011 Placebo
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Subjects are eligible for the study if they meet all of the following Inclusion Criteria:
- Age ≥18 years of age, male or female
- Body mass index (BMI) 18-26 kg/m2 (inclusive) for Part A healthy subjects and BMI 18-40 kg/m2 (inclusive) for Part B acute gout flare subjects; Part B acute gout flare subjects also needed to meet the following criteria
- Meet ACR 2015 preliminary criteria for the classification of acute arthritis of primary gout
- Other inclusion criteria set by protocol
Who cannot take part
- Have received an experimental agent within 1 month or 5 times half-life (whichever is longer) prior
- Have live or attenuated vaccination in the 3 months before randomization or plan to receive that during this trial
- Blood donation or blood loss of more than 400 mL within 8 weeks before the screening
- Have a history of severe infection, severe trauma, or major surgical procedures within 6 months before the screening
- Have a history of drug abuse, drug dependence, or a positive result in a drug screen within 12 months before the screening
- Secondary gout (e.g., gout induced by chemotherapy, transplant-related gout)
- Difficulties in venous blood collection or a history of dizziness when encountering blood or needles
- History of malignancy
- Has a history of neuropsychiatry or any other disease/ailment that is unsuitable for this clinical trial at the discretion of the Investigator; Part B acute gout flare subjects also needed to exclude the following criteria:
- Infection/septic arthritis, or other acute inflammatory arthritis
- Subjects meeting any of the following criteria are not eligible to attend this clinical study:
- Female during pregnancy or lactation
- Other exclusion criteria set by protocol
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanised monoclonal antibody injection in healthy Chinese subjects (Part A) and subjects with acute gout flare (Part B)
The 2 groups in the trial
- PlaceboPlacebo, for comparison
IBI3011 placebo group
Treatment: IBI3011 Placebo
- IBI3011Treatment being tested
IBI3011 group
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Anti-IL-RAP Humanized Monoclonal Antibody Injection in Chinese Subjects
- Record updated
- 16 November 2026